Market closedNon-fractional
Aquestive Therapeutics/AQST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Ticker
AQST
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Warren, United States
Employees
135
Website
www.aquestive.com
AQST Metrics
BasicAdvanced
$314M
Market cap
-
P/E ratio
-$0.44
EPS
2.80
Beta
-
Dividend rate
Price and volume
Market cap
$314M
Beta
2.8
Financial strength
Current ratio
6.279
Quick ratio
5.733
Long term debt to equity
-93.78
Total debt to equity
-94.984
Interest coverage (TTM)
-1.91%
Management effectiveness
Return on assets (TTM)
-12.74%
Return on equity (TTM)
39.53%
Valuation
Price to revenue (TTM)
4.405
Price to book
-8.6
Price to tangible book (TTM)
-8.32
Price to free cash flow (TTM)
-8.527
Growth
Revenue change (TTM)
10.65%
Earnings per share change (TTM)
-31.11%
3-year revenue growth (CAGR)
2.23%
3-year earnings per share growth (CAGR)
-34.81%
What the Analysts think about AQST
Analyst Ratings
Majority rating from 9 analysts.
AQST Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12M
-9.09%
Net income
-$13M
58.02%
Profit margin
-106.66%
73.83%
AQST Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.10
-$0.03
-$0.12
-$0.17
-
Expected
-$0.12
-$0.11
-$0.08
-$0.08
-$0.12
Surprise
-15.25%
-73.50%
50.00%
106.48%
-
AQST News
AllArticlesVideos
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
GlobeNewsWire·2 days ago
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
GlobeNewsWire·4 days ago
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aquestive Therapeutics stock?
Aquestive Therapeutics (AQST) has a market cap of $314M as of July 27, 2024.
What is the P/E ratio for Aquestive Therapeutics stock?
The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of July 27, 2024.
Does Aquestive Therapeutics stock pay dividends?
No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Aquestive Therapeutics dividend payment date?
Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.
What is the beta indicator for Aquestive Therapeutics?
Aquestive Therapeutics (AQST) has a beta rating of 2.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Aquestive Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.